HCV Elimination: A Multi-society Perspective on Progress, Gaps and Next Steps

Achieving hepatitis C virus (HCV) elimination remains an important global public health priority.This webinar will review where global HCV elimination progress has succeeded, stalled and what strategies could get us back on track. This activity is intended for hepatologists, gastroenterologists, infectious disease specialists, primary care physicians, public health specialists, nurses, pharmacists, physician assistants, transplant coordinators, patient advocates, and healthcare providers. Others interested in global Hepatitis C elimination are also welcome to view the recording.

This is a collaborative International Webinar Sponsored by:

  1. American Association for the Study of Liver Diseases (AASLD).
  2. European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Viral Hepatitis
  3. Infectious Diseases Society of America (IDSA)
  4. International Network on Health, Hepatitis, and Substance Use (INHSU)

Presentation 1: Has HCV treatment as prevention delivered on its promise?
     Natasha Martin, DPhil/PhD (Organization: INHSU; Country: USA)

Presentation 2: Why are we still missing people with HCV in 2026?
     Norah Terrault, MD, MPH (Organization: AASLD; Country: USA)

Presentation 3: What will change the curve by 2030?
     Federico García, PharmD, PhD (Organization: ESCMID ESGVH; Country: Spain)

Learning Objectives

Upon completion of this activity, a participant should be able to:

  • Evaluate global and US national progress regarding hepatitis C virus (HCV) elimination, highlighting both successes and challenges
  • Discuss populations at risk for HCV and what gaps need to be addressed to bolster microelimination efforts
  • Identify strategies that could get HCV elimination progress back on track

Course summary

Course opens: 
10/13/2026
Course expires: 
10/26/2029

Ponni Perumalswami, MD, FAASLD
Nothing to Disclose

Susanna Naggie, MD, MHS (IDSA)

Harrys Torres, MD, FAASLD (IDSA/AASLD)
Grant/Research Support: National Cancer Institute

Natasha Martin, PhD
Grant/Research Support: Gilead, AbbVie

Norah Terrault, MD, MPH, FAASLD
Data Safety Monitoring Board: University of Pittsburgh
Intellectual Property Rights: Elsevier
Scientific Consultant/Advisor: CCO Hepatitis, Bluejay Therapeutics, GlaxoSmithKline, EIT Pharma, Madrigal
Grant/Research Support: NIH, Gilead, GlaxoSmithKline, Roche-Genentech, Helio Health, Durect, Eiger, Madrigal, Hoffman LaRoche
Bluejay Therapeutics, VIR Biotech, Aligos Therapeutics, Immunocore

Federico Garcia, PharmD, PhD
Nothing to Disclose

Please login or register to take this course.

Required Hardware/software

Required Hardware/software

Please ensure that your device meets the minimum requirements prior to accessing the course content.

Minimum Requirements

  • Newest version of Google Chrome, Microsoft Edge, Firefox, or Safari
  • Operating system: Windows 7+, Mac OS X 10.7+, or Ubuntu 10+
  • Internet connection with 1+ Mbps

If you experience delay or lag, please close other tabs, browsers, and programs while streaming your video. For slow connections, it may also help to hardwire your Internet connection, instead of using a wireless network connection.

If you experience issues while accessing any course materials, please reach out to our support team by submitting a support request.